Ratings Sanofi India Limited

Equities

SANOFI

INE058A01010

Market Closed - Bombay S.E. Other stock markets 03:30:49 16/05/2024 pm IST			5-day change	1st Jan Change
8,571 ^INR	+2.47%		+3.95%	+6.24%

14/05	Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead	CI
14/05	Sanofi India Limited Declares Final Dividend for the Financial Year Ended December 31, 2023	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.5 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SANOFI INDIA LIMITED	+6.24%	230.87Cr		B-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.98%	4.39TCr		B-
OTSUKA HOLDINGS CO., LTD.	+24.56%	2.31TCr		B+
SANDOZ GROUP AG	+19.25%	1.53TCr		-
CIPLA LIMITED	+14.03%	1.36TCr		B+
ZYDUS LIFESCIENCES LIMITED	+46.40%	1.2TCr		B
ONO PHARMACEUTICAL CO., LTD.	-10.14%	699.72Cr		B+
THE MEDICINES COMPANY	-0.05%	678.76Cr	-	-
STADA ARZNEIMITTEL	-8.87%	572.55Cr	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	559.68Cr		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders